| |
WAVESENSE TO EXHIBIT AT AACR, BOOTH 2141,
SHOWCASING NEW MELANOMA CELL DETECTION METHOD.
March 1, 2006
WaveSense will showcase its new Melanoma (9.2.27)
XRC™ Kit April 1-5th, at the 2006 annual meeting of
the American Association of Cancer Research. The Melanoma
kit utilizes WaveSense’s Xenographic Retention Chromatography™
(XRC) technology, and a combination of four antibodies. EpiSep
XRC™ is an open platform for rapid and sensitive capture
and sorting of live cells, proteins, and genes for interrogation.
The kit antibodies include; Monoclonal 9.2.27 for recognition
of Melanoma-associated Chondroitin Sulfate Proteogylcan (MCSP)
complex for capture on magnetic particles; and three biotin
labeled monoclonal antibodies – M2-7C10, A103, and T311,
which are used to detect and recognize, respectively, the
Mart-1, Melan-A and Tyrosinase epitopes in melanoma cells.
The combination of antibodies, in conjunction with EpiSep
XRC™, provides excellent specificity and sensitivity,
and demonstrates the significant workflow improvements for
detection of rare cells in a variety of samples. Some of the
samples include blood, tissue preparation, and cell culture.
The latest XRC™ Cellular assays in bench
top and automated formats will be exhibited at AACR. For more
information, please visit booth number 2141.
EpiSep™ employs WaveSense’s patented
Xenographic Retention Chromatography™ (XRC) technology
for sensitive, direct detection of specific cells or molecules
from any type of sample. XRC™ simultaneously integrates
immunoaffinity, nulceoaffiinity, magnetic density and mobile
phase chromatography principles into a single, nanoseparations
platform.
Visit the AACR website
WaveSense, Inc. develops, manufactures, and
commercializes leading-edge diagnostic nanotechnologies for
use in the fields of clinical chemistry, biotechnology and
drug discovery.
Contact:
Jeff Barbieri
WaveSense, Inc.
949-341-1980
|
|
|
